Sophia Lugo, Radar Therapeutics CEO
May 23, 2024 08:00 AM EDT
Financing

Start­up launch­es with ‘RNA sen­sor’ tech­nol­o­gy from Stan­ford and MIT to bet­ter con­trol mR­NA ther­a­pies

Ryan Cross

Senior Science Correspondent

Find­ing a way to de­liv­er ge­net­ic med­i­cines to the right parts of the body is one of the most tech­no­log­i­cal­ly vex­ing prob­lems in the biotech …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Associate Director, Market Insights and Analytics

Celldex Therapeutics

Hampton, NJ, USA

TRENDING NOW

Au­toim­mune CAR-T da­ta dump: Kyver­na, Ca­balet­ta shares fall af­ter un­veil­ing ear­ly-stage re­sults

Gilead can­cer drug ma­grolimab showed wor­ry­ing trends around death

Stephen Squin­to talks writ­ing checks and next-gen obe­si­ty drugs as JP Mor­gan clos­es first $500M+ biotech fund

Rare pe­di­atric dis­ease vouch­ers face un­cer­tain fu­ture af­ter Sep­tem­ber

With new da­ta, As­traZeneca makes the case for its BTK in­hibitor in a first-line set­ting

sponsored

De-risk­ing the pa­tient jour­ney in cell ther­a­pies: Six key con­sid­er­a­tions

A service from the Financial Times